Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biological Psychiatry|April 23, 2003
Research issues in the study of difficult-to-treat depressionA John Rush, Michael E Thase, Sanjay Dubé
Journal of Clinical Psychopharmacology|March 28, 2015
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentSusan G Ball, Sarah Atkinson, JonDavid Sparks, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|November 18, 2014
Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)Lee Baer, Susan Ball, JonDavid Sparks, et al.
Journal of Psychiatric Research|November 14, 2009
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depressionSanjay Dubé, Mary Anne Dellva, Marcia Jones, et al.
Bipolar Disorders|September 12, 2007
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depressionSanjay Dubé, Gary D Tollefson, Michael E Thase, et al.
The Journal of Clinical Psychiatry|March 6, 2007
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderMichael E Thase, Sara A Corya, Olawale Osuntokun, et al.
Biological Psychiatry|April 23, 2003
Assessing and interpreting treatment effects in longitudinal clinical trials with missing dataCraig H Mallinckrodt, Todd M Sanger, Sanjay Dubé, et al.
The American Journal of Psychiatry|July 3, 2008
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophreniaAnantha Shekhar, William Z Potter, Jeffrey Lightfoot, et al.
The Journal of Clinical Psychiatry|December 9, 2003
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label studySara A Corya, Scott W Andersen, Holland C Detke, et al.
Schizophrenia Bulletin|August 30, 2008
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Aaron S Kemp, Nina R Schooler, Amir H Kalali, et al.
Pageof 1